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Opioid receptors are currently classified as Mu (μ), Delta (δ), Kappa (κ) plus the opioid
related nociceptin/orphanin FQ (N/OFQ) peptide receptor (NOP). Despite compelling evi-
dence for interactions and benefits of targeting more than one receptor type in producing
analgesia, clinical ligands are Mu agonists. In this study we have designed a Mu-NOP ago-
nist named DeNo. The Mu agonist component is provided by dermorphin, a peptide isolated
from the skin of Phyllomedusa frogs and the NOP component by the endogenous agonist
N/OFQ.
Methods
We have assessed receptor binding profile of DeNo and compared with dermorphin and N/
OFQ. In a series of functional screens we have assessed the ability to (i) increase Ca2+ in
cells coexpressing recombinant receptors and a the chimeric protein Gαqi5, (ii) stimulate the
binding of GTPγ[35S], (iii) inhibit cAMP formation, (iv) activate MAPKinase, (v) stimulate
receptor-G protein and arrestin interaction using BRET, (vi) electrically stimulated guinea
pig ileum (gpI) assay and (vii) ability to produce analgesia via the intrathecal route in rats.
Results
DeNo bound to Mu (pKi; 9.55) and NOP (pKi; 10.22) and with reasonable selectivity. This
translated to increased Ca2+ in Gαqi5 expressing cells (pEC50 Mu 7.17; NOP 9.69),
increased binding of GTPγ[35S] (pEC50 Mu 7.70; NOP 9.50) and receptor-G protein interac-
tion in BRET (pEC50 Mu 8.01; NOP 9.02). cAMP formation was inhibited and arrestin was
activated (pEC50 Mu 6.36; NOP 8.19). For MAPK DeNo activated p38 and ERK1/2 at Mu
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but only ERK1/2 at NOP. In the gpI DeNO inhibited electrically-evoked contractions (pEC50
8.63) that was sensitive to both Mu and NOP antagonists. DeNo was antinociceptive in rats.
Conclusion
Collectively these data validate the strategy used to create a novel bivalent Mu-NOP pep-
tide agonist by combining dermorphin (Mu) and N/OFQ (NOP). This molecule behaves
essentially as the parent compounds in vitro. In the antonocicoeptive assays employed in
this study DeNo displays only weak antinociceptive properties.
Introduction
While the majority of clinical opioids mainly target the Mu (μ) receptor, work in cell and ani-
mal models would suggest targeting two or more opioid receptors simultaneously may produce
drugs with reduced harmful effects. A large body of this work has concentrated on simulta-
neous targeting of the Delta (δ) receptor to produce drugs with attenuated tolerance profiles
[1–3]. Work in in vitro cell based systems has demonstrated that antagonism of Delta, or dis-
ruption of the Mu-Delta heterodimer, leads to recycling of the Mu receptor, rather than ubiqui-
tination after activation and internalisation [4–6]. These findings were confirmed in animal
studies with Delta knockout mice showing a complete attenuation of morphine tolerance, as
did preproenkephalin knockout mice [7]. Despite this compelling evidence no Mu-Delta
mixed ligands have yet reached the clinic.
The nociceptin/orphanin FQ (N/OFQ) peptide receptor (NOP) is a comparatively new
member of the opioid family and is often referred to as a ‘non-opioid branch” due to little or
no affinity for the non-selective opioid antagonist, naloxone [8]. The NOP receptor is located
throughout the pain pathways producing anti-opioid effects supraspinally and analgesic effects
spinally [8–11]. NOP has been shown to co-localise in the pain pathways with Mu [9]. Activa-
tion of the NOP receptor has demonstrated several advantages over the classical opioid recep-
tors. For instance, NOP agonists are able to efficiently treat neuropathic pain, a condition
which classical opioid do not adequately treat [8, 9]. Of particular note, intrathecal co-adminis-
tration of N/OFQ and morphine in non-human primates led to a potentiation of morphine-
induced antinociception, without the associated morphine-induced side effects (itch) [12].
From a cellular perspective, Mu and NOP have been demonstrated to co-express in close prox-
imity and display differential signalling activity in vitro, suggesting the formation of a heterodi-
mer [13–15].
Results from both in vitro and in vivomodels have subsequently led to the development of a
number of mixed molecules targeted to Mu and NOP. One of the first examples of a mixed
NOP-opioid ligand was [Dmt1]N/OFQ(1–13)-NH2, a non-selective opioid agonist acting at
both the classical opioid receptors and NOP. [Dmt1]N/OFQ(1–13)-NH2 demonstrated potent
and sustained activity in vivo in the monkey tail withdraw assay, with a 30-fold increase in
potency over N/OFQ [16]. The most recently developed Mu-NOP bifunctional pharmaco-
phore is cebranopadol. Cebranopadol is a full Mu agonist and a high efficacy partial agonist at
NOP [17]. In rat models, cebranopadol demonstrated a long duration of action and did not dis-
rupt motor coordination or respiration. Furthermore, cebranopadol produced tolerance by 26
days compared to only 11 days for morphine [17, 18]. The results demonstrated by cebranopa-
dol would suggest that targeting of Mu and NOP could provide substantial improvement in the
treatment of pain. To further understand the interactions between Mu and NOP, a detailed
Mu-NOPMixed Ligands
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examination of the interactions of a full agonist dual-targeted drug needs to be further made.
In order to further explore the interactions between Mu and NOP we have synthesized a mixed
Mu-NOP agonist named DeNo (Fig 1). The Mu agonist component is provided by dermor-
phin, a peptide isolated from the skin of Phyllomedusa frogs [19]. The NOP component is the
endogenous agonist N/OFQ. We have assessed receptor binding, upstream and downstream
signalling in cells and tissues and assessed in vivo spinal anti-nociceptive effects in rats.
Methods
Materials
The reference molecules, dermorphin, Leu-enkephalin, Dynorphin-A and N/OFQ were
synthesised in house (Department of Chemical and Pharmaceutical Sciences, University of Fer-
rara). Tritiated UFP-101 ([3H]-UFP-101) was synthesized as described previously [20]. Triti-
ated diprenorphine ([3H]-DPN) and [3H]-cyclic Adenosine monophosphate (cAMP) were
purchased from Perkin Elmer. Naloxone was purchased from Sigma-Aldrich Co. (Dorset, U.
Fig 1. Chemical structure of DeNo.
doi:10.1371/journal.pone.0156897.g001
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K.). Naltrindole (Delta antagonist) and [D-Pen2, D-Pen5]-enkephalin (Delta agonist, DPDPE)
were purchased from Tocris (Abingdon, UK). Antibodies and protein ladders were purchased
from Cell Signalling (Boston, MA, USA). All tissue culture media and supplements were
obtained from Invitrogen (Paisley, U.K.).
Synthesis of DeNo
DeNo was assembled using a classical thiol-Michael reaction; reacting in solution a thiol func-
tion inserted in the N/OFQ sequence with a maleimide function inserted into the dermorphin
sequence. In detail, [Cys18]N/OFQ-NH2 was synthesized and purified in house while the syn-
thesis of dermorphin elongated in the C-terminal with Lys(maleimide) (Fig 1) was performed
using classical solid phase peptide synthesis techniques [21]. Selective deprotection of the Lys
side chain of the intermediate [Lys(Dde)8]dermorphin-resin was achieved following the proce-
dure of Bycroft et al [22]. To a suspension of protected [Lys(Dde)8] Der-resin (300 mg) in
anhydrous tetrahydrofuran (3 ml), 2% hydrazine in methanol (5 ml) was added. The reaction
mixture was stirred under argon for 30 min, then filtered and the resin washed 3 times with
dimethylformamide (DMF,5 ml) and CH2Cl2 (5 ml). To a stirred solution of 4-(2,5-dioxo-
2,5-dihydro-1Hpyrrol- 1-yl)butanoic acid (0.2 mmol) in (DMF) (5 mL) at 0°C, [O-(7-azaben-
zotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate] (HATU) (0.2 mmol) and
4-methylmorpholine (0.2 mmol) were added. After 10 min, [Lys(free side chain)8]dermorpin-
resin (200 mg, 0.67 meq/gr; 0.13 meq) was added and the reaction mixture stirred at room tem-
perature for 4 h. The solution was then filtered and the resin washed 5 times with DMF (5 ml)
and 3 times with CH2Cl2 (5 ml). The protected [Lys(Mal)
8]dermorphin-resin was treated with
reagent B (trifluoroacetic acid (TFA) / H20 / phenol / triisopropylsilane 88: 5: 5: 2; v/v; 10 mL /
0.2 g of resin) for 1.5 h at room temperature [23]. After filtration of the resin, the solvent was
concentrated under vacuum and the residue triturated with ethyl ether. Crude peptide was
purified by preparative reverse phase HPLC and lyophilized. Finally, [Cys18]N/OFQ-NH2 was
reacted with [Lys(Mal)8]dermorphin following a procedure reported in literature and then
purified by preparative HPLC to give the desired final product after lyophilisation [24].
Cell Culture
Cells were grown in either Hams F12 (for Chinese Hamster Ovary; CHOhMu, CHOhDelta and
CHOhKappa cells), DMEM/Hams F12 1:1 (for CHOhNOP cells and SH-SY5Y cells) or DMEM
(for HEK-293 cells). The media contained 100 μg ml-1 streptomycin, 2.5 μg ml-1 fungizone,
100 IU ml-1 penicillin and 10% foetal bovine serum. G418 (200 μg ml-1) was used to maintain
CHO cells expressing classical opioid receptors. Stock media containing G418 (200 μg ml-1)
and hygromycin B (200 μg ml-1) was used to maintain CHOhNOP cells. HEK-293 cells perma-
nently co-expressing the fusion proteins NOP-Rluc and Gβ1-RGFP or NOP-Rluc and β-
arrestin 2-RGFP and SH-SY5Y cells co-expressing the fusion proteins Mu-Rluc and Gβ1-RGFP
or Mu-Rluc and β-arrestin 2-RGFP were prepared using the pantropic retroviral expression
system by Clontech as described previously [25]. Cells were used for experiments once conflu-
ent. CHO cells stably co-expressing the human recombinant NOP or Mu receptors as well as
the C-terminally modified Gαqi5 protein were generated and used in calcium mobilisation
studies as previously described [26, 27]. Cells were cultured in culture medium consisting of
DMEM/Hams F12 (50/50) supplemented with 10% foetal calf serum (FCS), penicillin (100 IU/
ml), streptomycin (100 mg/ml), geneticin (G418; 200 μg/ml) and hygromycin B (100 μg/ml).
In all cases, cell cultures were kept at 37°C in 5% CO2/humidified air. The sources of cells used
can be found in references [27] and [28].
Mu-NOPMixed Ligands
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Membrane preparation
In the radioligand displacement binding assays, homogenization/wash buffer consisting of 50
mM Tris-HCl pH to 7.4 with KOH, for CHOhMu, CHOhDelta and CHOhKappa or additional 5
mMMgSO4 for CHOhNOP was used. Homogenisation buffer (50 mM Tris and 0.2 mM EGTA
pH 7.4 with NaOH) was used in GTPγ[35S] assays. Membranes were centrifuged at 20374 g for
10 min at 4°C. This process was repeated at least three times. The resulting pellet was resus-
pended in an appropriate amount of the necessary buffer and the protein concentration was
determined by Lowry assay [29].
Displacement Binding Assay
Membrane protein (40 μg) was incubated in 0.5ml of 50 mM Tris, 0.5% BSA and ~0.8nM
[3H]-DPN (for CHOhMu, CHOhDelta and CHOhKappa) or ~0.8nM [
3H]-UFP-101 (for CHONOP
cells), as well as varying concentrations (10 μM-1pM) of the reference ligand DeNo. Non-spe-
cific binding was determined in the presence of 10 μM naloxone for CHOhMu, CHOhDelta and
CHOhKappa or 1μM of N/OFQ for CHONOP cells. Samples were incubated for 1 hr at room
temperature and reactions were terminated by vacuum filtration, onto PEI-soaked Whatman
GF/B filters, using a Brandel harvester. The concentration of displacing ligand producing 50%
displacement was corrected for the competing mass of radioligand to yield pKi, a measure of its
affinity [3].
Calcium mobilisation assay
When confluence was reached (3–4 days), cells were seeded at a density of 50,000 cells/well
into 96-well black, clear bottom plates. After 24 h incubation, the cells were loaded with
medium supplemented with 2.5 mM probenecid, 3 μM of the calcium sensitive fluorescent dye
Fluo-4 AM and 0.01% pluronic acid, for 30 min at 37°C. Afterwards, the loading solution was
aspirated and 100 μl/well of assay buffer (Hank’s balanced salt solution supplemented with 20
mMHEPES, 2.5 mM probenecid, and 500 μM Brilliant Black (Aldrich)) was added. Serial dilu-
tions of ligands were made in Hank’s balanced salt solution / HEPES (20 mM) buffer (contain-
ing 0.02% BSA fraction V). After placing both plates (cell culture and compound plate) into
the FlexStation II (Molecular Device, Union City, CA 94587, US), fluorescence changes were
measured at 37°C. Online additions were carried out in a volume of 50μl/well. Maximum
change in fluorescence, expressed in percent of baseline fluorescence, was used to determine
agonist response [27].
GTPγ[35S] binding Assay
Membrane protein (40 μg) was incubated in 0.5 ml volume of 50 mM Tris, 0.2 mM EGTA, 1
mMMgCl2, 100 mM NaCl, 0.1% BSA, 0.15 mM bacitracin; pH 7.4, GDP (33 μM), and*150
pM GTPγ[35S]. Varying concentrations of reference ligands (dermorphin, N/OFQ, Dynor-
phin-A and Leu-enkephalin) or DeNo (1 pM—10μM) was added prior to incubation. Non-
specific binding was determined in the presence of unlabeled GTPγS (10μM). Samples were
incubated at 30°C for 1 h with gentle agitation. Reactions were terminated by vacuum filtration
through dry Whatman GF/B filters, using a Brandel harvester [3]
cAMP Assay
CHOhMu and CHOhNOP whole cells were suspended in Krebs/HEPES buffer, containing isobu-
tylmethylxanthine (1mM) and forskolin (1μM). For Mu, dermorphin and DeNo were included
Mu-NOPMixed Ligands
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at 1μM concentrations. At NOP, N/OFQ and DeNo were included at 1μM concentrations.
cAMP was extracted and assayed using a protein binding assay as described previously [30].
Western blotting- MAPK detection
ERK1/2 and p38 MAPK activity in CHOhMu and CHOhNOP cells was detected by Western blot-
ting techniques. CHOhMu and CHOhNOP cells were serum starved for 24 hours prior to treat-
ment. Drugs were added for 15 minutes in Krebs Buffer [composition: 115mM NaCl, 4.7mM
KCl, 2mM CaCl2, 1.2mMMgCl2, 25mMNaHCO3, 8mM glucose]. For Mu; dermorphin and
DeNo were added at 1μM concentrations. At NOP; N/OFQ, and DeNo were added at 1μM
concentrations. Signalling was terminated via Lysis Buffer [Tris-HCl (pH 7.4), 20 mM; 1%
(vol/vol); Triton X-100, 10% (vol/vol); glycerol, NaCl, 137 mM; EDTA, 2 mM; β-glyceropho-
sphate, 25 mM; sodium orthovanidate; 1 mM; phenylmethanesulfonylfluoride, 500 μM; leu-
peptin, 0.1 mg/ml; benzamidine, 0.2 mg/ml; pepstatin, 0.1 mg/m] followed by centrifugation
(10187 g, 10 minutes, 4°C), with the supernatant removed and added to an equal volume of
2XSDS buffer [composition: 100mM Tris-HCl (pH 6.8), 2% SDS, 10% Glycerol, 0.1% Bromo-
phenol Blue]. Samples were denatured (heated 100°C for 5 minutes) and separated by 10%
SDS-PAGE; transferred onto nitrocellulose paper in a semi-dry buffer (composition: 48mM
Tris Base, 39mM Glycine, 0.037% w/v SDS, 20%Methanol) and blocked using conventional
western blotting techniques. To detect phosphorylated ERK1/2 and phosphorylated p38 activ-
ity, pERK1/2 antibodies (1:6000 dilution) and p38 antibodies (1:3000dilution), diluted in
TBS-T solution [50 mM Tris-base, 150 mM NaCl, 0.1% Tween-20 (vol/vol), pH 7.5] with
0.01% (wt/vol) BSA, were used to probe the membrane and left overnight at 4°C. Horseradish
peroxidase-conjugated secondary anti-rabbit antibodies (1hr room temperature, 1:1000 dilu-
tion in TBS-T with 5% milk) were used to visualise immune-reactive bands, followed by chemi-
luminescence detection using the ChemiDoc™MP Imaging System (Bio-Rad). In order to
ensure equal gel loading, membranes were stripped and reprobed for total ERK1/2 and total
p38 MAPK. Membranes were incubated in Restore Plus™ (Fisher) for 15 minutes then thor-
oughly washed in TBS-T, following which they were blocked as previously described. The
membrane was then probed using the specific antibody for ERK 1/2 (NEBL, 1:3000 dilution),
or p38 (NEBL, 1:3000 dilution), overnight (4°C) followed by addition of the secondary anti-
body and chemiluminescence detection. Normalisation of total protein levels for each sample
was then achieved by representing levels of pERK1/2 and p-p38 as a proportion of total ERK1/
2 or total p38 protein. Data were analyzed using the “Origin 9” software and images analysed
using Image Lab software (Bio-Rad, UK) [31].
BRET Assay
Membrane extracts taken from HEK-293 and SH-SY5Y cells stably expressing NOP-RLuc and
Mu-RLuc respectively together with Gβ1-RGFP were used to assess the effects of drugs on
receptor/G protein interaction in concentration response curve experiments. For G-protein
experiments, enriched plasma membrane aliquots from transfected cells were prepared by dif-
ferential centrifugation; cells were detached with PBS/EDTA solution (1 mM, pH 7.4 NaOH)
then, after 5 min 500 g centrifugation, Dounce-homogenized (30 strokes) in cold homogeniza-
tion buffer (TRIS 5 mM, EGTA 1 mM, DTT 1 mM, pH 7.4 HCl) in the presence of sucrose
0.32 M. Three further centrifugations were performed at 1000 g (4°C) and the supernatants
kept. Two 25,000 g (4°C) subsequent centrifugations (the second in the absence of sucrose)
were performed for separating enriched membranes that, after discarding the supernatant,
were kept in ultrapure water at -80°C [32]. The protein concentration in membrane prepara-
tions was determined using the QPRO-BCA kit (Cyanagen Srl, Bologna, IT) and a Beckman
Mu-NOPMixed Ligands
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DU 520 spectrophotometer (Brea, CA, USA). Luminescence in membranes was recorded in
96-well untreated white opaque microplates (PerkinElmer, Waltham, MA, USA) using the Vic-
tor 2030 luminometer (PerkinElmer, Waltham, MA, USA). For the determination of receptor/
G-protein interaction, membranes (3 μg of protein) prepared from cells co-expressing NOP or
Mu-RLuc and Gβ1-RGFP were added to wells in Dulbecco’s PBS. For the determination of
receptor/β-arrestin 2 interaction, cells co-expressing NOP-RLuc or Mu-RLuc and β-arrestin
2-RGFP were plated 24 h before the experiment in poly-D-Lysine treated plates (100,000 cells/
well), while for Mu expressing cells untreated plates were used. The cells were prepared for the
experiment substituting the medium with DPBS supplemented with MgCl2 (0.5 mM) and
CaCl2 (0.9 mM). Coelenterazine, at a final concentration of 5 μM, was injected 15 minutes
prior to reading the cell plate. Receptor/G protein interaction was measured in cell membranes
to exclude the participation of other cellular processes (i.e. arrestin recruitment, internaliza-
tion). Different concentrations of ligands in 20 μL of PBS—BSA 0.03% were added and incu-
bated for an additional 5 min before reading luminescence. All experiments were performed at
room temperature.
Guinea pig ileum bioassay
With approval of Animal Subjects Review Board of the University of Ferrara and from the Ital-
ian Ministry of Health (PROT-186) ileum tissues were taken from male albino guinea pigs of
350–400 g (Pampaloni, Pisa, Italy). The animals were treated in accordance with European
guidelines (86/609/ECC) and national regulations (DL 116/92). They were housed in 560 x 320
x 180 mm cages (Techinplast), three per cage, under standard conditions (22°C, 55% humidity,
12 h light/dark cycle, light on at 7:00 h) with food (complete feed for guinea pig, Mucedola,
Milano, Italy) and water ad libitum. The day of the experiment the animals were killed with an
isofluorane overdose. Bioassay experiments were performed as previously described [33]. The
tissues were suspended in 5 ml organ baths containing Krebs solution (composition in mM:
NaCl 118.5, KCl 4.7, MgSO4 1.2, KH2PO4 1.2, NaHCO3 25, CaCl2 1.8, glucose 10), hexametho-
nium bromide 22 μM, benadril 0.34 μM and oxygenated with 95% O2 and 5% CO2. The tem-
perature was set at 37°C. At resting tension, 1 g was applied to the tissues. Tissues were
stimulated through two platinum electrodes with a supramaximal rectangular pulse of 1 ms
duration, 0.05 Hz frequency, 80V amplitude. Electrically evoked contractions were measured
isotonically by means of Basile strain gauge transducers (Basile 7006; srl Ugo Basile, Varese,
Italy) and recorded with a computer–based acquisition system (Power Lab 8, ADInstruments,
USA). After an equilibration period of about 60 min, the contractions induced by electrical
field stimulation were stable. At this time, cumulative concentration response curves to ago-
nists were constructed (0.5 log unit steps). Antagonists were injected into the baths 15 minutes
before constructing agonist concentration response curves.
In Vivo Studies
For all the experiments described below, male Sprague-Dawley rats (Harlan, Varese, Italy),
weighing approximately 280-300g at the beginning of the experimental procedure, were used.
Animals were housed in CeSAL (Centro Stabulazione Animali da Laboratorio, University of
Florence) and used at least one week after their arrival. One rat was housed per cage (size
26x41 cm); animals were fed with standard laboratory diet and tap water ad libitum, and kept
at 23±1°C with a 12 h light/dark cycle, light at 7 a.m. All animal manipulations were carried
out according to the European Community guidelines for animal care (DL 116/92, application
of the European Communities Council Directive of 24 November 1986 (86/609/EEC). The eth-
ical policy of the University of Florence complies with the Guide for the Care and Use of
Mu-NOPMixed Ligands
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Laboratory Animals of the US National Institutes of Health (NIH Publication No. 85–23,
revised 1996; University of Florence assurance number: A5278-01). Formal approval to con-
duct the experiments described was obtained from the Animal Subjects Review Board of the
University of Florence and from the Italian Ministry of Health (N°54/2014-B). Experiments
involving animals have been reported according to ARRIVE guidelines [34]. All efforts were
made to minimize animal suffering and to reduce the number of animals used. All animals
were monitored daily using a scoring system (based on: Appearance, Food and Water Intake,
Clinical Signs, Natural Behaviour and Provoked Behaviour [35]. Maximum score is 20 and ani-
mals reaching 10 are euthanized. In the experiments reported here no animals reached this
score and none died before the end of the experiment) and at the end of the experiment were
euthanized by CO2 overdose.
Intrathecal catheterization
Rats were anaesthetised with 2% isoflurane and an intrathecal catheter was surgically
implanted according to the method of Yaksh & Rudy (1976) [36]. Rats were shaved on the
back of the neck and placed in the stereotaxic frame with the head securely held between ear
bars. The skin over the nape of the neck was cleaned with ethyl alcohol and incised for 1 cm.
The muscle on either side of the external occipital crest was detached and retracted to expose
about 3–4 mm2 of the atlanto-occipital membrane. The membrane was incised by a needle,
which led to the escape of cerebrospinal fluid. The caudal edge of the cut was lifted and about
7.0 cm of 28G polyurethane catheter (0.36 mm outer diameter; 0.18 mm inner diameter; Alzet,
USA) was gently inserted into the intrathecal space in the midline, dorsal to the spinal cord
until the lumbar enlargement. The exit end of the catheter was connected to 4.0 cm polyure-
thane tube (0.84 mm outer diameter; 0.36 mm inner diameter) and was taken out through the
skin, flushed with saline solution, sealed and securely fixed on the back of the head with a silk
wire. Animals were placed in individual cages until recovery. All animals used during beha-
vioural tests did not show surgery induced motor impairment as evaluated by Rota rod test.
Animals presenting any kind of motor disability were excluded from the behavioural measure-
ments. Behavioral measurements were performed on 5 rats for each treatment.
Intrathecal drug treatments
Dermorphin and DeNo were dissolved in sterile saline solution. Acute measures were per-
formed after the intrathecal (i.t.) infusion of 0.1–1 nmol dermorphin and DeNo. All com-
pounds were administered in a final volume of 10 μl. Behavioral tests were carried out after 15,
30, 45, 60, 90, 120 and 180 min.
Paw Pressure test
Nociceptive threshold was determined with an analgesimeter (Ugo Basile, Varese, Italy),
according to the method described by Leighton et al. (1988) [37]. Briefly, a constantly
increasing pressure was applied to a small area of the dorsal surface of the paw using a blunt
conical probe by a mechanical device. Mechanical pressure was increased until vocalization
or a withdrawal reflex occurred while rats were lightly restrained. Vocalization or withdrawal
reflex thresholds were expressed in grams. Rats scoring below 40 g or over 75 g during the
test before drug administration were rejected. For analgesia measures, mechanical pressure
application was stopped at 150 g. All experiments were performed by a researcher blind to
drug treatment.
Mu-NOPMixed Ligands
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Rota-rod test
Rota-rod apparatus (Ugo Basile, Varese, Italy) consisted of a base platform and a rotating rod
with a diameter of 6 cm and a non-slippery surface. The rod was placed at a height of 25 cm
from the base. The rod, 36 cm in length, was divided into 4 equal sections by 5 disks. Thus, up
to 4 rats were tested simultaneously on the apparatus, with a rod-rotating speed of 10 rpm. The
integrity of motor coordination was assessed on the basis of the number of falls from the rod in
60s measured 15, 30, 45, 60, 90, 120 and 180 min after treatments.
Data analysis
Data are expressed as mean±SEM or with confidence intervals as appropriate. For more than 2
groups, data are analysed using ANOVA with post-hoc testing using Dunnett’s or Bonferroni’s
test as appropriate. Where there are only 2 groups paired or unpaired t-tests were used. P val-
ues of less than 0.05 were considered significant. All curve fitting was accomplished using
Graphpad-Prism (V6). The concentration of drug producing 50% of the maximum response
(pEC50) and the maximum response (Emax) are quoted. In gpI experiments the antagonist
potency (pKb) is calculated from the rightward shift of the agonist concentration response
curve by a fixed antagonist concentration.
Results
Displacement Binding assay
In displacement binding studies at CHOhMu, dermorphin and DeNo displaced the binding of
[3H]-DPN in a concentration dependent and saturable manner (Fig 2). DeNo (pKi 9.55) dem-
onstrated a significant increase in affinity at Mu, when compared to the parent compound der-
morphin (8.69). At CHOhNOP, DeNo displaced [
3H]-UFP-101 in a concentration dependent
and saturable manner (Fig 2). DeNo (10.22) displayed a similar pKi value, for NOP, to its par-
ent compounds N/OFQ (10.69) (Fig 2, Table 1). At CHOhDelta, DeNo (8.12) demonstrated an
increase in affinity compared to its parent compounds. Dermorphin displayed an affinity of
7.17, while N/OFQ failed to displace [3H]-DPN at the Delta receptor. Furthermore, DeNo
(7.34) showed affinity for the Kappa receptor, whereas the parent compounds (dermorphin
and N/OFQ) failed to displace [3H]-DPN at this receptor (Fig 2, Table 1).
Calcium mobilisation assay
In CHO cells stably expressing the Gαqi5 chimeric protein and the human Mu receptor, der-
morphin produced a concentration-dependent stimulation of calcium mobilisation with high
potency (pEC50 8.07) and maximal effects (234% over basal). DeNo showed similar maximal
effect (209% over basal) but approximately 10-fold lower potency (pEC50 7.17) (Fig 3). In
CHOhNOP cells stably expressing the Gαqi5 chimeric protein, N/OFQ evoked a concentration
dependent stimulation of calcium release with high potency (pEC50 9.85) and maximal effect
(279% over basal). DeNo showed similar potency (pEC50 9.69) and maximal effect (244% over
basal) to N/OFQ (Fig 3 and Table 2).
GTPγ[35S] Assay
Dermorphin and DeNo stimulated the binding of GTPγ[35S] in a concentration dependent
and saturable manner at the Mu receptor (Fig 4). DeNo (Emax 2.68) demonstrated a similar
maximal response to that of dermorphin (2.63). The pEC50 values for DeNo (7.77) showed no
significant difference to that of the parent compound, dermorphin (7.83) (Fig 4, Table 3). At
CHOhNOP, N/OFQ and DeNo stimulated the binding of GTPγ[
35S] in a concentration
Mu-NOPMixed Ligands
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dependent and saturable manner (Fig 4). DeNo produced a maximal response (Emax 2.49) sim-
ilar to that of its parent compound, N/OFQ (2.57). The pEC50 value of 9.50 achieved by DeNo
was similar to that of N/OFQ (9.05). (Table 3). Leu-enkephalin and DeNo stimulated the bind-
ing of GTPγ[35S] in a concentration dependent and saturable manner in membranes
Table 1. Displacement Binding Profiles.
pKi
CHOhMu CHOhNOP CHOhDelta CHOhKappa
Reference ligand - - 10.02 (±0.26) 10.16 (±0.02)
dermorphin 8.69 (±0.10) <5 7.17 (±0.11) <5
N/OFQ <5 10.69 (±0.10) <5 <5
DeNo 9.55 (±0.10)* 10.22 (±0.09) 8.12 (±0.11)* 7.34(±0.13)*
pKi values for both the reference ligands, dermorphin, N/OFQ and DeNo. Data are displayed as mean (±SEM) of n = 5 experiments. Statistical
significance (*) demonstrates p<0.05, using one-way ANOVA with Dunnett’s correction, when compared to the reference ligands dermophin (Mu), N/OFQ
(NOP), Naltrindole (Delta) and Dynorphin-A (Kappa).
doi:10.1371/journal.pone.0156897.t001
Fig 2. Displacement Binding. Displacement of tritiated Diprenorphine ([3H]-DPN) by dermorphin, DeNo, and reference ligands at
(A) CHOhMu, (B) CHOhDelta, (C) CHOhKappa and the displacement of tritiated UFP-101 ([
3H]-UFP-101) by DeNo and N/OFQ at (D)
CHONOP cell membranes. Data are means (SEM) of n5 experiments for all cell lines. Reference ligands: dermorphin; naltrindole;
dynorphin-A; N/OFQ, (nociception/orphanin FQ).
doi:10.1371/journal.pone.0156897.g002
Mu-NOPMixed Ligands
PLOS ONE | DOI:10.1371/journal.pone.0156897 June 7, 2016 10 / 22
expressing Delta receptors (Fig 4). DeNo (Emax 1.84) produced a maximal response similar to
that of the endogenous Delta peptide, Leu-enkephalin (1.90). However, the pEC50 value for
DeNo (6.78) was significantly lower than that of Leu-enkephalin (8.50) (Table 3). At CHOh-
Kappa, dynorphin-A and DeNo stimulated the binding of GTPγ[
35S] in a concentration depen-
dent and saturable manner (Fig 4). DeNo (Emax 2.36) produced a maximal response similar to
that of dynorphin-A (2.33). The pEC50 value of DeNo (5.91) was significantly lower than that
of dynorphin-A (9.36) (Table 3).
Cyclic AMP assay
To further assess functional activity of DeNo, inhibition of cyclic AMP (cAMP) formation was
assessed. Since DeNo demonstrated a higher affinity and potency at Mu and NOP, assays were
performed using CHOhMu and CHOhNOP cells only. Addition of forskolin in CHOhMu cells
lead to a 24.3 (±1.79) fold increase in cAMP production, when compared to basal activity (Fig
3). Co-incubation of 1μM dermorphin, or 1μMDeNo reverses the effects of forskolin, return-
ing cAMP levels to basal. In CHOhNOP cells, forskolin stimulation leads to a 21.23 (±3.86) fold
increase in cAMP production, when compared to basal activity. The addition of 1μMN/OFQ
Fig 3. CalciumMobilisation. Concentration-response curves to N/OFQ, dermorphin and DeNo in calciummobilisation assay using CHOhMu
cells (A) and CHONOP cells (B). Data is represented as percentage increase over basal fluorescence intensity units (FIU). Data are the




pEC50 (CL95%) Emax ± SEM pEC50 (CL95%) Emax ± SEM
N/OFQ 9.85(9.37–10.33) 279 ± 44% Inactive
dermorphin crc incomplete 8.07(7.85–8.29) 234 ± 14%
DeNo 9.69(9.35–10.03) 244 ± 6% 7.17(6.91–7.43) 209 ± 15%
Effects of N/OFQ, dermorphin and DeNo in calcium mobilisation experiments performed in CHO cells stably expressing the human NOP or Mu receptor
and the Gαqi5 protein. Data are expressed as the mean (±SEM) of at least 3 experiments performed in duplicate. For potency values 95% confidence limits
were indicated. Data have been analysed with one way ANOVA followed by the Dunnett’s test for multiple comparisons; p values less than 0.05 were
considered to be significant.
doi:10.1371/journal.pone.0156897.t002
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reverses forskolin stimulated cAMP production. The addition of 1μMDeNo has a similar
effect, returning cAMP levels to basal.
Detection of MAPK activity throughWestern blot Densitometry
In CHOhMu cells, basal activity of phosphorylated p38 (p-p38) was 9.67±1.39% of total. Follow-
ing stimulation by 1μM dermorphin, this activity rose to 25.02±1.18%, this was statistically sig-
nificant. Administration of DeNo (28.41±1.27%) led to a similar increase in p-p38 activity. In
phosphorylated ERK1/2 (p-ERK1/2) assays, basal activity was measured at 2.75 ± 0.83% of
total. The addition of 1 μM dermorphin (34.23 ± 4.97%) or DeNo (34.30 ± 4.5%) produced a
statistically significant increase over basal activity (Fig 5). In CHOhNOP cells, phosphorylation
of p38 was not detected. In studies assessing the activation of p-ERK1/2, basal activity was
Fig 4. GTPγ[35S] Response Curves. Ligand stimulated GTPγ[35S] binding by DeNo and reference ligands are shown at A) CHOhMu, (B)
CHOhDelta, (C) CHOhKappa and (D) CHONOP cell membranes. Graphs are represented as a stimulation factor, which is the fold change in activity
when compared to basal. Data are mean (±SEM) for n = 5 experiments.
doi:10.1371/journal.pone.0156897.g004
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measured at 4.24 ±1.26% of total. The addition of 1μMN/OFQ (63.08 ±7.97%) or DeNo (70.46
±10.63%) produced a statistically significant increase over basal activity (Fig 5).
BRET Assays
In HEK-293 membranes, N/OFQ promoted NOP-RLuc/G-protein-RGFP interaction in a con-
centration-dependent manner with high potency (pEC50 9.22) and a maximal effect corre-
sponding to 0.42±0.04 stimulated BRET ratio. Dermorphin was very weak only increasing
BRET ratio at micromolar concentrations (Fig 6, Table 4). In SH-SY5Y membranes, dermor-
phin produced a concentration dependent stimulation of G-protein interaction, also with high
potency (pEC50 8.13). In this cell type, the maximal effect was larger at 1.39±0.14 stimulated
BRET ratio. N/OFQ was very weak increasing BRET ratio only at micromolar concentrations.
Under the same experimental conditions, DeNo was tested in both cells lines. In HEK-293
membranes, DeNo mimicked the stimulatory effect of N/OFQ with similar potency (9.02) and
maximal effect (α 1.01) (Fig 6). In SH-SY5Y membranes, DeNo concentration dependently
increased BRET ratio with similar potency and maximal effect (pEC50 8.03 and α 0.98) to der-
morphin (Fig 6, Table 4). HEK-293 and SH-SY5Y cells stably expressing the human NOP or
Mu (NOP/Mu-RLuc) receptors and β-arrestin 2-RGFP were used to evaluate NOP and Mu
interaction with β-arrestin 2.
In HEK-293 cells, N/OFQ promoted NOP/β-arrestin 2 interaction with high potency
(pEC50 8.21) and maximal effect corresponding to 0.092±0.003 stimulated BRET ratio. Der-
morphin was completely inactive (Fig 7, panel A). In SH-SY5Y cells, dermorphin stimulated
Mu β-arrestin 2 interaction with a potency (pEC50) of 7.00. Maximal effect was 0.43 stimulated
BRET ratio (again in this cell line simulated ratio was larger). N/OFQ was completely inactive
(Fig 7). Under the same experimental conditions in HEK-293 cells DeNo mimicked the stimu-
latory effect of N/OFQ (pEC50 8.19 and α 1.03). In SH-SY5Y cells, DeNo promoted Mu/β-
arrestin 2 interaction mimicking the stimulatory effect of dermorphin (α 0.98) but with 4 fold
lower potency (pEC50 6.36) (Fig 7, Table 5).
Guinea pig ileum bioassay
DeNo was assessed in the electrically stimulated guinea pig ileum. In this preparation, concen-
tration response curves to DeNo were assessed in comparison with N/OFQ and dermorphin
(Fig 8). N/OFQ inhibits contractions induced by electrical field stimulation in a concentration
dependent manner, with a pEC50 of 8.03 (7.84–8.23) and maximal effect of 71±4%. Dermor-
phin mimicked the effects of N/OFQ with higher potency and maximal effects (pEC50 9.55
(9.33–9.77) Emax 86 ± 2%). The new compound, DeNo, inhibited electrically induced twitch,
with a potency of 8.63 and maximal effects similar to those of dermorphin (Emax 90 ± 1%).
Table 3. GTPγS Functional Activity.
CHOhMu CHOhNOP CHOhDelta CHOhKappa
pEC50 Emax α pEC50 Emax α pEC50 Emax α pEC50 Emax α
Control 7.83(7.45–8.21) 2.61(±0.14) 1 9.05(8.77–9.34) 2.57(±0.17) 1 8.5(8.19–8.81) 1.9(±0.10) 1 9.34(9.22–9.49) 2.3(±0.09) 1
DeNo 7.77(7.54–7.80) 2.68(±0.12) 1.03 9.5(9.33–9.68) 2.49(±0.25) 0.96 6.78(6.59–6.97)* 1.84(±0.03) 0.97 5.92(5.78–6.02)* 2.23(±0.14) 0.97
Agonist activity of DeNo at CHOhMu, CHOhNOP, CHOhDelta and CHOhKappa. Antagonist affinity was determined against N/OFQ (NOP). Relative intrinsic
activity (α) was determined by removal of basal activity and as a ratio of reference ligands (full agonist) Emax. All experiments are represented as the mean
(±SEM) of n5 experiments. For potency values 95% confidence limits were indicated.
* p<0.05 t-test against the reference ligand [Dermophin (Mu), N/OFQ (NOP), Naltrindole (Delta) and Dynorphin-A (Kappa)].
doi:10.1371/journal.pone.0156897.t003
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In order to determine the site of action of DeNo in the guinea pig ileum, antagonist assays
were undertaken. The standard non-selective opioid antagonist naloxone (100 nM) does not affect
the inhibitory action of N/OFQ, while 100 nM SB-612111 was able to shift to the right the concen-
tration response curve to N/OFQ with a pKb of 8.36. In contrast, the effects of dermorphin were
sensitive to naloxone (pKb 8.57) but not to SB-612111 (Fig 8). Finally, the effects of DeNo were
challenged with naloxone, SB-612111, and the cocktail of the two antagonists. Naloxone antago-
nized the inhibitory effect of DeNo producing a rightward shift of the concentration response
curve and no modification of maximal effects. A pKb value of 7.54 was derived from these experi-
ments. SB-612111 was also able to counteract DeNo effects by producing a displacement to the
right of the concentration response curve; a pKb value of 7.07 was derived from these experiments.
When the two antagonists were assayed together they displayed a clear additive effect.
Paw pressure Test
Time-courses were produced for both dermorphin and DeNo given intrathecally (i.t.) in rats
subjected to the plantar test. Dermorphin produced significant antinociceptive effects (Fig 9A).
Similar effects were measured in response to i.t. DeNo which was less potent producing statisti-
cally significant effects only at the top dose of 1 nmol (Fig 9B). However it should be ubders-
cored that in the same range of doses both compounds impaired animal performance in the
rotarod test (data not shown).
Discussion
In this study we have characterised a novel peptide bivalent Mu-NOP ligand, DeNo; created by
combining dermorphin and N/OFQ. DeNo bound to Mu and NOP receptors and was ~5fold
Fig 5. The Activation of ERK1/2 and p38. A) The activity of phosphorylated p38 compared to total p38 at
CHOhMu caused by dermorphin (1μM) and DeNo (1μM). B) The activity of phosphorylated ERK1/2 compared
to total ERK1/2 at CHOhMu caused by dermorphin (1μM) and DeNo (1μM). C) The activity of phosphorylated
ERK1/2 at CHOhNOP caused by N/OFQ (1μM) and DeNo (1μM). All data are after a 15 minute incubation
period. Data are mean (±SEM) for n = 5. *p<0.05; according to ANOVA followed by Dunnett’s test for multiple
comparison. Representative blots are shown above mean data.
doi:10.1371/journal.pone.0156897.g005
Fig 6. G-protein Recruitment Measured Using BRET.Membrane extracts taken from HEK-293 and SH-SY5Y cells stably
expressing NOP-RLuc and Mu-RLuc respectively together with Gβ1-RGFP were used. Concentration response curves to N/OFQ,
dermorphin and DeNo for receptor/G protein interaction in membranes of cells expressing the NOP (A) and Mu (B) receptors. Data are
the mean ± SEM of at least 3 experiments performed in duplicate.
doi:10.1371/journal.pone.0156897.g006
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NOP selective. There was between 1 and 2 logs selectivity over Delta and Kappa receptors. At
conventional upstream (GTPγ[35S]) and downstream (cAMP) assays and in Ca2+ mobilisation
experiments using chimeric G-protein constructs DeNo was a full agonist at both Mu and
NOP. In BRET assays to assess receptor G-protein interaction and arrestin recruitment, DeNo
also behaved as a full agonist. Moreover, DeNo activated ERK1/2 as a full agonist at Mu and
NOP; there was no activation of p38 at NOP. In a more intact preparation DeNo inhibited con-
traction of the electrically stimulated gpI via simultaneous activation of NOP and Opioid
receptors and was antinociceptive via the i.t. route in rats.
At the receptor, the most striking difference was a log increase in DeNo binding affinity at
Mu compared to dermorphin and this may result from the structure of the linker between the
two ‘pharmacophores’. Comparing CHO data and taking into account different assays/buffer
systems there was a marked difference in pKi / pEC50 for Mu falling 60 fold at GTPγ[
35S]
(upstream) and 331 fold at the chimeric G-protein (downstream). In contrast at NOP there
was a 7 and 3 fold difference in affinity compared to potency. As the point of interrogation
(assay) moved further down the signal transduction cascade the difference in potency at Mu
Table 4. Assessment of G-protein and Receptor Interactions Using BRET.
Gβ1-protein
NOP Mu
pEC50(CL95%) α ± SEM pEC50 (CL95%) α ± SEM
N/OFQ 9.22(9.14–9.30) 1 crc incomplete
dermorphin crc incomplete 8.13(7.87–8.39) 1
DeNo 9.02(8.87–9.17) 1.01 ± 0.01 8.01(7.39–8.63) 0.98 ± 0.03
Effects of compounds tested on NOP/Gβ1- HEK-293 and Mu/Gβ1- SH-SY5Y protein interactions. Data are expressed as the mean (±SEM) of at least 3
experiments performed in duplicate. For potency values 95% confidence limits were indicated. Maximal effects elicited by the ligands were expressed as
intrinsic activity (α) related to the standard control.
doi:10.1371/journal.pone.0156897.t004
Fig 7. β-arrestin 2 recruitment measured using BRET.Membrane extracts taken from HEK-293 and SH-SY5Y cells stably expressing
NOP-RLuc and Mu-RLuc respectively together with β-arrestin 2-RGFP were used. Concentration response curves to N/OFQ, dermorphin and
DeNo for receptor/β-arrestin 2 interaction in cells expressing the NOP (panel A) and Mu (panel B) receptors. Data are the mean ± SEM of at least 4
experiments performed in duplicate.
doi:10.1371/journal.pone.0156897.g007
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and NOP increased. For example in GTPγ[35S] assay DeNo was 38 fold more potent at NOP
and 331 fold more potent in the chimeric G-protein assay. In all assays DeNo was a full agonist.
If there was amplification or a coupling reserve then the potency values should shift leftwards
rather than rightwards. This rightward shift was more marked at Mu than NOP and could be
explained by buffer composition and end point. It is well documented that the chimeric G-
Table 5. β-arrestin Recruitment.
β-arrestin 2
NOP Mu
pEC50 (CL95%) α ± SEM pEC50 (CL95%) α ± SEM
N/OFQ 8.21(7.97–8.45) 1 inactive
dermorphin inactive inactive 7(6.59–7.42) 1
DeNo 8.19(7.93–8.46) 1.03 ± 0.02 6.36(6.08–6.63) 0.98 ± 0.04
Effects of compounds tested on NOP/β-arrestin 2—HEK-293 and Mu/ β-arrestin 2 SH-SY5Y protein interactions. Data are expressed as the mean (±SEM)
of at least 4 experiments performed in duplicate. For potency values 95% confidence limits were indicated. Maximal effects elicited by the ligands were
expressed as intrinsic activity (α) related to the standard control.
doi:10.1371/journal.pone.0156897.t005
Fig 8. Guinea Pig IleumContractile Response. (A) Concentration-response curves to N/OFQ, dermorphin and DeNo in the electrically
stimulated guinea-pig ileum. Effects of naloxone, SB-612111 and a cocktail of both on concentration-response curves to N/OFQ (B),
dermorphin (C) and DeNo (D) in electrically stimulated guinea-pig ileum. Data are presented as a % of control twitch and the mean ± SEM
for at least n = 3.
doi:10.1371/journal.pone.0156897.g008
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protein assay suffers from hemi-equilibrium problems and we have discussed this in detail pre-
viously [38].
Using BRET based assays, we have been able to assess receptor/G protein interaction and
arrestin recruitment. These end points were examined in HEK cells for NOP and SH-SY5Y
cells for Mu; this is a minor drawback in comparison with the other assays reported but
because we have used dermorphin and N/OFQ then we can cross compare. In all assays, the
parent compounds and DeNo behaved in essentially the same manner (potency) and as full
agonists. A possible confounder is that SH-SY5Y cells have been shown to express both the
Delta receptor and, more relevantly, the NOP receptor; at very low expression levels [39]. Pre-
vious work with Mu/NOP heterodimers has demonstrated that activation of NOP often leads
to a reduction in the potency of Mu agonists throughout the cell signalling cascade [15]. It is
possible in this cell line that DeNo is engaging both Mu and NOP. It has been known for some
time that opioid receptors couple to MAPK with some variation in coupling [40, 41]. In CHO
cells expressing recombinant Mu and NOP there were marked differences. ERK1/2 was ubiqui-
tously activated but p38 was only activated by Mu. ERK1/2 is typically involved in proliferative
and differentiation responses but there is good evidence for a role in more chronic opioid
receptor activation and possibly withdrawal [42–44]. This kinase along with p38 also plays a
role in apoptosis [45]; the distinction of roles is not clear cut. In terms of activation, two path-
ways have been suggested-the first involving a typical G-protein mediated event and the second
via an arrestin–MAPK protein scaffold. That arrestin is activated is confirmed by the BRET
assay but without full concentration response curves and pertussis toxin sensitivity experi-
ments it is not possible to delineate the relative importance of these pathways. The fact that
dermorphin and N/OFQ behaved as full agonists with no striking differences in potency sug-
gests no ligand bias as expected for naturally occurring agonists. We have used the gpI as a
more intact bioassay that (1) endogenously expresses both Mu and NOP [33] and (2) links the
in vitro recombinant data set to the in vivo behavioural experiments. In this preparation, N/
OFQ was sensitive to the non-peptide antagonist SB-612111 but not naloxone; dermorphin
was sensitive to naloxone but not SB-612111. These antagonists displayed lower potency when
tested against DeNo whose concentration response curve was additively shifted when a cocktail
of antagonists was used. Collectively, these results demonstrated that the biological action of
DeNo in this preparation is due to the simultaneous activation of NOP and Mu receptors
despite the greater loss of potency at Mu than at NOP found in recombinant systems.
Fig 9. In Vivo activity of DeNo.Dose response curve to dermorphin (panel A) and DeNo (panel B) in rats subjected to the
paw pressure test. Data (as mechanical threshold measured in g) are the mean ± SEM of 5 rats in each group. *p<0.05,
according to one way ANOVA followed by the Dunnett’s test for multiple comparisons. An increase is indicative of an
antinociceptive (or analgesic) response.
doi:10.1371/journal.pone.0156897.g009
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In vivo, after spinal administration in rats dermorphin (present results) and N/OFQ [46]
elicited similar antinociceptive actions. Under the same experimental conditions, DeNo mim-
icked the effects of dermorphin and N/OFQ being neither more potent nor more effective.
This result contrasts with the extensive literature evidence suggesting that the simultaneous
activation of Mu and NOP receptor elicits synergistic antinociceptive effects both in rodents
[47–49] and in non-human primates [12, 16, 50, 51]. In vitro studies clearly demonstrated that
DeNo is able to bind and activate both Mu and NOP receptor in the same range of concentra-
tions; this may not be the case in vivo. A similar situation has been previously well documented
in the studies of the MDAN series of compounds [52]. Under the present experimental condi-
tions there were almost no differences between doses inducing antinociceptive effects and
those disrupting animal performance on the rotarod. Further studies are needed to assess in
detail any potential spinal antinociceptive actions of DeNo.
In conclusion we have created a novel bivalent Mu-NOP peptide agonist by combining der-
morphin (Mu) and N/OFQ (NOP); this molecule behaves essentially as the parent compounds.
Despite this promising profile, analgesic actions of DeNo are poor in the model employed here.
As a mixed molecule, this ligand represents a useful addition to the non-peptides BU08028 [53,
54], the SRI-International compounds exemplified by SR16435 [54, 55] cebranopadol and the
peptide [Dmt1]N/OFQ(1–13)-NH2. DeNo may be a useful tool, particularly in vitro for investi-
gating the consequences of the simultaneous activation of NOP and mu receptors.
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